Global patent landscape of programmed cell death 1: implications of the rapid expansion

References

• Agata Y, Nishimura H, Ishida Y, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996;8(5):765–772.
   PubMed Web of Science ®Google Scholar
• Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704.
   PubMed Web of Science ®Google Scholar
• Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027–1034.
   PubMed Web of Science ®Google Scholar
• Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793–800.
   PubMed Web of Science ®Google Scholar
• Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4(127):127ra37.
   PubMed Web of Science ®Google Scholar
• Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114(8):1537–1544.
   PubMed Web of Science ®Google Scholar
• Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers and combinations. Sci Transl Med. 2016;8(328):328rv4.
   PubMed Web of Science ®Google Scholar
• Balar AV, Weber JS. PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunol Immunother. 2017;66(5):551–564.
   PubMed Web of Science ®Google Scholar
• Storz U. Intellectual property issues of immune checkpoint inhibitors. mAbs. 2016;8(1):10–26.
   PubMed Web of Science ®Google Scholar
• Collin M. Immune checkpoint inhibitors: a patent review (2010-2015). Expert Opin Ther Pat. 2016;26(5):555–564.
   PubMed Web of Science ®Google Scholar
• Zarganes-Tzitzikas T, Konstantinidou M, Gao Y, et al. Inhibitors of programmed cell death 1 (PD-1): a patent review (2010-2015). Expert Opin Ther Pat. 2016;26(9):973–977.
   PubMed Web of Science ®Google Scholar
• Bastian M, Heymann S, Jacomy M. Gephi: an open source software for exploring and manipulating networks. Proceedings of the 3rd International AAAI Conference on Weblogs and Social Media; 2009 May 17-20; San Jose, CA.; p.361–362.
   Google Scholar
• Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11(11):3887–3895.
   PubMed Web of Science ®Google Scholar
• Honjo T, Ishida Y, Shinohara T. A novel peptide related to human programmed cell death and DNA encoding it. EP 0670369. 1995.
   Google Scholar
• Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11(2):141–151.
   PubMed Web of Science ®Google Scholar
• Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001;291(5502):319–322.
   PubMed Web of Science ®Google Scholar
• Melese T, Lin SM, Chang JL, et al. Open innovation networks between academia and industry: an imperative for breakthrough therapies. Nat Med. 2009;15(5):502–507.
   PubMed Web of Science ®Google Scholar
• Getz KA, Kaitin KI. Open innovation: the new face of pharmaceutical research and development. Expert Rev Clin Pharmacol. 2012;5(5):481–483.
   PubMed Web of Science ®Google Scholar
• Trajtenberg M. A penny for your quotes: patent citations and the value of innovations. RAND J Econ. 1990;21(1):172–187.
   Web of Science ®Google Scholar
• Xu J, Kong X, Qiu L, et al. Research and development of anti-Alzheimer’s drugs: an analysis based on technology flows measured by patent citations. Expert Opin Ther Pat. 2014;24(7):791–800.
   PubMed Web of Science ®Google Scholar
• Kong X, Hu Y, Cai Z, et al. Dendritic-cell-based technology landscape: insights from patents and citation networks. Hum Vaccin Immunother. 2015;11(3):682–688.
   PubMed Web of Science ®Google Scholar
• Zhang M, Kong X, Zheng J, et al. Research and development of antibiotics: insights from patents and citation network. Expert Opin Ther Pat. 2016;26(5):617–627.
   PubMed Web of Science ®Google Scholar
• Korman A, Srinivasan M, Wang C, et al. Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics. WO 2006121168. 2006.
   Google Scholar
• Irving B, Cheung J, Chiu H, et al. Anti-PD-L1 antibodies and their use to enhance T-cell function. WO 2010077634. 2010.
   Google Scholar
• Korman A, Selby M, Wang C, et al. Human monoclonal antibodies to programmed death ligand 1 (PD-L1). WO 2007005874. 2007.
   Google Scholar
• Eisenbach-Schwartz M, Baruch K, Rosenzweig N. Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the cns. WO 2015136541. 2015.
   Google Scholar
• Finnefrock AC, Fu TM, Freed DC, et al. PD-1 binding proteins. WO 2009114335. 2009.
   Google Scholar
• Carven GJ, Van EH, Dulos GJ. Antibodies to human programmed death receptor PD-1. WO 2008156712. 2008.
   Google Scholar
• Freeman G, Sharpe A, Dorfman D, et al. Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway. WO 2006133396. 2006.
   Google Scholar
• Collins M, Wood C, Carreno B, et al. Antibodies against PD-1 and uses therefor. WO 2004056875. 2004.
   Google Scholar
• Langermann S. Targeted costimulatory polypeptides and methods of use to treat cancer. WO 2010027827. 2010.
   Google Scholar
• Langermann S. Simultaneous inhibition of PD-L1/PD-L2. WO 2011066342. 2011.
   Google Scholar
• Cogswell J, Goldberg S, Gupta A, et al. Cancer immunotherapy by disrupting PD-1/PD-L1 signaling. US 2013309250. 2013.
   Google Scholar
• Honjo T, Minato N, Iwai Y, et al. Immunopotentiating Compositions. WO 2004004771. 2004.
   Google Scholar
• Wood C, Freeman G. PD-1, a receptor for B7-4, and uses therefor. WO 2001014557. 2001.
   Google Scholar
• Queva C, Morrow M, Hammond S, et al. Targeted binding agents against B7-H1. WO 2011066389. 2011.
   Google Scholar
• Ahmed R, Amara R, Freeman G, et al. Compositions and methods for the treatment of infections and tumors. WO 2008083174. 2008.
   Google Scholar
• Tyson KL. Biological products: humanised agonistic anti-PD-1 antibodies. WO 2011110621. 2011.
   Google Scholar
• Freeman G, Ahmed R, Jones T, et al. Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor. WO 2010036959. 2010.
   Google Scholar
• Maxwell B, Bedoya F, Saba G, et al. Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells. WO 2016168595. 2016.
   Google Scholar
• Nastri H, Iffland C, Leger O, et al. Anti-PD-L1 antibodies and uses thereof. WO 2013079174. 2013.
   Google Scholar
• Geng X, Kong X, Hu H, et al. Research and development of therapeutic mAbs: an analysis based on pipeline projects. Hum Vaccin Immunother. 2015;11(12):2769–2776.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med Title. 2012;366:2443–2454.
   PubMed Web of Science ®Google Scholar
• Dai S, Jia R, Zhang X, et al. The PD-1/PD-Ls pathway and autoimmune diseases. Cell Immunol. 2014;290(1):72–79.
   PubMed Web of Science ®Google Scholar
• Bagley CE, Tvarno CD. Pharmaceutical public-private partnerships in the United States and Europe: moving from the bench to the bedside. Harvard Bus Law Rev. 2013;4:373–401.
   Google Scholar
• Belderbos R, Cassiman B, Faems D, et al. Co-ownership of intellectual property: exploring the value-appropriation and value-creation implications of co-patenting with different partners. Res Policy. 2014;43(5):841–852.
   Web of Science ®Google Scholar
• Belderbos R, Faems D, Leten B, et al. Technological activities and their impact on the financial performance of the firm: exploitation and exploration within and between firms. J Prod Innov Manag. 2010;27:869–882.
   Web of Science ®Google Scholar
• Hagedoorn J, Van Kranenburg H, Osborn RN. Joint patenting amongst companies: exploring the effects of inter-firm R&D partnering and experience. Manage Decis Econ. 2003;24:71–84.
   Google Scholar
• Maurseth PB, Verspagen B. Knowledge spillovers in Europe: a patent citations analysis. Scand J Econ. 2002;104(4):531–545.
   Web of Science ®Google Scholar
• Jaffe AB, De Rassenfosse G. Patent citation data in social science research: overview and best practices. Working paper, no. 21868. Cambridge, MA:NBER; 2017.
   Google Scholar
• Bergman K, Graff GD. The global stem cell patent landscape: implications for efficient technology transfer and commercial development. Nat Biotechnol. 2007;25(4):419–424.
   PubMed Web of Science ®Google Scholar
• Clarkson G. Patent informatics for patent thicket detection: a network analytic approach for measuring the density of patent space. Honolulu: Academy of Management; 2005.
   Google Scholar
• Jeitschko TD, Zhang N. On the challenges facing patent pooling in biotechnology. J Intell Prop Rights. 2014;19(2):113–122.
   Google Scholar
• Schmidt C. Negotiating the RNAi patent thicket. Nat Biotechnol. 2007;25(3):273–275.
   PubMed Web of Science ®Google Scholar
• BMS press release [Internet]. Bristol-Myers Squibb and Ono Pharmaceutical Company enter settlement and license agreement with Merck to resolve PD-1 antibody patent litigation; 2017 Jan 20. Available from: https://news.bms.com/press-release/partnering-news/bristol-myers-squibb-and-ono-pharmaceutical-company-enter-settlement-a
   Google Scholar
• Merck news release [Internet]. Merck announces settlement and license agreement resolving KEYTRUDA® (pembrolizumab) patent litigation; 2017 Jan 20. Available from: http://www.mrknewsroom.com/news-release/corporate-news/merck-announces-settlement-and-license-agreement-resolving-keytruda-pemb
   Google Scholar
• Collin M. Immune checkpoint inhibitors: the battle of giants. Pharm Pat Anal. 2017;6(4):135–137.
   PubMed Web of Science ®Google Scholar
• Park H. Written description problems of the monoclonal antibody patents after Centocor v. Abbott. Harvard J Law Technol. 2014 Mar 13. Available from: http://jolt.law.harvard.edu/digest/written-description-problems-of-the-monoclonal-antibody-patents-after-centocor-v-abbott
   Google Scholar